![i.comformation about tracking devices put in ambify i.comformation about tracking devices put in ambify](https://weartotrack.com/wp-content/uploads/2020/06/navigation-1048294_1280-1-768x432.jpg)
Worldwide, around 21million people are affected. In 2014, the World Health Organization (WHO) reported that as many as 50 per cent of patients on prescription medications do not take their drugs as directed.Ī study published in December 2018 by the Amsterdam University of Applied Sciences claimed 75 per cent of patients with schizophrenia quit their meds within 18 months.īetween 930,000 and 2.3million people in the US are thought to have schizophrenia or a similar disorder. Past research has found that non-adherence – refusing to take medication properly or regularly – is a particular problem for doctors treating schizophrenic patients.
![i.comformation about tracking devices put in ambify i.comformation about tracking devices put in ambify](https://greenwaldllp.com/wp-content/uploads/2016/11/17-gps.jpg)
'The idea that we’re giving this group of patients a pill that, in fact, transmits info about them from inside their body to the people that are involved in their treatment almost seems like a confirmation of the worst paranoias of the worst patients.' Past research has found around 50 per cent of patients given regular medication don't take it properly, and this may be even higher for patients with schizophrenia. In this way, doctors can collect accurate, reliable and real-time data about whether their patient is sticking to their prescription.
![i.comformation about tracking devices put in ambify i.comformation about tracking devices put in ambify](https://assets-global.website-files.com/5bcf95411e70df20404f914c/5deaebd35373c1f131e6a5a5_blog-header-20191202.jpg)
I.comformation about tracking devices put in ambify Patch#
The patch then synchronises with a mobile app on the patient's smartphone or tablet, and sends data to their doctor over the internet to show whether the pill has been taken. That completes a circuit between coatings of copper and magnesium on either side, generating a tiny electric charge. The sensor has no battery or antenna but is activated when it gets wet from stomach juices. Ingestion can be recorded within between 30 minutes and two hours of the patient swallowing the drug. The chip, containing copper, magnesium and silicon, sends a signal to a patch worn on the patient's arm when the pill is taken. It combined a tried and tested schizophrenia drug, Abilify, with a metallic chip the size of a grain of sand. In 2017 Abilify M圜ite became the first pill containing a tracking sensor to be approved by the US's Food and Drug Administration.